TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

56 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

51 studies on the map

BOTOX® vs. XEOMIN® for Chronic Migraine — Naval Medical Center Camp Lejeune, JacksonvilleA Study of Eptinezumab in Pediatric Participants With Episodic Migraine — Ki Health Partners LLC DBA New England Institute for Clinical Research, StamfordSafety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia — Esperanza Clinical, MurrietaA Study of Buntanetap in Participants With PD — University of Alabama at Birmingham, BirminghamEfficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects — The Belinga Clinic, Fort SmithA Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease — Banner Sun Health Research Institute, Sun CityA Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years — Rehabilitation and Neurological Services /ID# 270782, HuntsvilleA Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease — Healthy Brain Clinic, Long BeachA Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) — Local Institution - 2609, ChandlerA Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine — Xenoscience Inc, PhoenixA Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT). — Banner Alzheimer's Institute, PhoenixA Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine — Central Research Associates, LLC (CRA) dba Flourish Research, BirminghamStudy to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) — Rehabilitation & Neurological Services /ID# 229969, HuntsvilleEASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Pinnacle Research Group, LLC, AnnistonA Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease — Banner Alzheimer?s Institute, PhoenixA Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5) — Gilbert Neurology Partners/CCT Research, GilbertSotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease — Stanford University Medical Center, StanfordEffectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines — Advocate Christ Medical Center Emergency Department, Oak LawnEpidemiology and Biomarker Study in Alzheimer's Disease — Care Access - Houston, HoustonVisualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease — Endeavor Health Systems, EvanstonA Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) — Fullerton Neurology and Headache Center, FullertonPET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620 — Perelman Center for Advance Medicine, PhiladelphiaA Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2) — Chandler Clinical Trials, LLC, ChandlerEvaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — Alliance For Multispecialty Research - Daphne, DaphneMaridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity — University of Alabama Saint Vincent's Birmingham, BirminghamA Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity — Advanced Cardiovascular, LLC, Alexander CityStudy of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine — Central Research Associates /ID# 260161, BirminghamA Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease — University of Alabama at Birmingham, BirminghamA Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease — University of Alabama at Birmingham, BirminghamScreening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies — University of Alabama at Birmingham, BirminghamA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) — Local Institution - 1227, ChandlerA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine — Mayo Clinic Hospital, PhoenixBiomarker Exploration in Aging, Cognition and Neurodegeneration — University of California, Irvine, IrvineA Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's — Northwestern University, EvanstonA Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation — University of Alabama in Birmingham, BirminghamA Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine — Yale-New Haven Children's Hospital - PIN, New HavenA Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine — Yale University School of Medicine, New HavenMasupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type — Advanced Research Center, Inc., AnaheimCombined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) — Nephrology of North Alabama, DecaturPreventing Alzheimer's With Cognitive Training — University of Florida, Gainesville[18F]PI-2620 Phase 3 Histopathological Study — Barrow Neurological Institute, PhoenixRandomized Study in Children and Adolescents With Migraine: Acute Treatment — Achieve Clinical Research, LLC d/b/a Accel Research Sites-Neurology and Neurodiagnostic of Alabama, BirminghamLong-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine — Perseverance Research Center, LLC, ScottsdaleBehavioral Activation Delivered Via Home-based Telehealth to Improve Functioning in Cardiovascular Disease Patients Recently Discharged From Inpatient Care — Ralph H. Johnson VA Medical Center, Charleston, SC, CharlestonPRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis — University of Alabama at Birmingham, BirminghamA Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation — University of Alabama in Birmingham, BirminghamA Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine — Rehabilitation & Neurological Services /ID# 248517, HuntsvilleA Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease — Site-049, BirminghamA Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) — Imaging Endpoints, ScottsdaleA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine — TrialSphere Corp, Merz Investigational Site #0010513, ChandlerA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine — TrialSphere Corp, Merz Investigational Site #0010513, Chandler